New J&J CEO Gorsky wants to grow device business | Wall Street Beat

April 25, 2012 by MassDevice staff

Incoming Johnson & Johnson CEO Alex Gorsky wants to expand the health care giant's already huge footprint in the medical device business, from which it derives about 40% of its revenues; also, Fitch holds steady on J&J's long-term debt; Accuray deepens its stake in Compact Particle Acceleration; Arrhythmia Research gets de-listing notice; CorMedix does too; and Gabelli slashes stake in Zoll; plus, a Funding Roundup and analysts' ups and downs. Wall Street Beat

When Alex Gorsky takes the helm at Johnson & Johnson (NYSE:JNJ) tomorrow, he'll become responsible for a company bedeviled by a series of high-profile, big-ticket recalls, a more than $1 billion legal settlement – and blessed with the world's largest medical device business.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.